Hikma Pharmaceuticals (LON:HIK)‘s stock had its “equal weight” rating reiterated by investment analysts at Morgan Stanley in a research note issued on Friday. They presently have a GBX 1,100 ($14.73) target price on the stock. Morgan Stanley’s price target suggests a potential upside of 6.69% from the company’s current price.
Other analysts have also issued research reports about the company. Numis Securities restated an “add” rating and issued a GBX 1,560 ($20.89) target price on shares of Hikma Pharmaceuticals in a report on Friday, August 11th. Peel Hunt reaffirmed a “hold” rating and issued a GBX 2,150 ($28.79) price target on shares of Hikma Pharmaceuticals in a research report on Thursday, August 17th. Jefferies Group lowered their price target on Hikma Pharmaceuticals from GBX 1,390 ($18.62) to GBX 1,045 ($13.99) and set a “hold” rating on the stock in a research report on Monday, August 21st. Goldman Sachs Group downgraded Hikma Pharmaceuticals to a “neutral” rating and lowered their price target for the company from GBX 2,600 ($34.82) to GBX 1,310 ($17.54) in a research report on Tuesday, August 22nd. Finally, Citigroup reaffirmed a “neutral” rating and issued a GBX 1,350 ($18.08) price target on shares of Hikma Pharmaceuticals in a research report on Thursday, August 24th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and two have issued a buy rating to the company’s stock. Hikma Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of GBX 1,186 ($15.88).
Hikma Pharmaceuticals (LON:HIK) opened at GBX 1,031 ($13.81) on Friday. Hikma Pharmaceuticals has a one year low of GBX 906.50 ($12.14) and a one year high of GBX 2,346 ($31.42).
Hikma Pharmaceuticals Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.